Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBITDA: 2019-2025

Historic EBITDA for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$15.4 million.

  • Keros Therapeutics' EBITDA rose 73.77% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 121.36%. This contributed to the annual value of -$210.8 million for FY2024, which is 24.06% down from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' EBITDA is -$15.4 million, which was up 61.36% from -$39.8 million recorded in Q2 2025.
  • Over the past 5 years, Keros Therapeutics' EBITDA peaked at $152.0 million during Q1 2025, and registered a low of -$58.7 million during Q3 2024.
  • In the last 3 years, Keros Therapeutics' EBITDA had a median value of -$43.3 million in 2023 and averaged -$25.8 million.
  • In the last 5 years, Keros Therapeutics' EBITDA plummeted by 556.80% in 2022 and then spiked by 413.59% in 2025.
  • Quarterly analysis of 5 years shows Keros Therapeutics' EBITDA stood at -$4.9 million in 2021, then slumped by 556.80% to -$32.0 million in 2022, then tumbled by 45.35% to -$46.5 million in 2023, then dropped by 14.64% to -$53.3 million in 2024, then spiked by 73.77% to -$15.4 million in 2025.
  • Its last three reported values are -$15.4 million in Q3 2025, -$39.8 million for Q2 2025, and $152.0 million during Q1 2025.